AbCellera's Menopause Drug Posts 'New Efficacy Benchmark' in Phase 2, Shares Surge 33%
ABCL has more than doubled off its 52-week low of $2.745 on elevated volume (5.4× avg).
Summary
ABCL635 hit a new efficacy benchmark in Phase 2 for menopausal hot flashes, with a single 600 mg dose cutting daily events by 8.8 vs 3.5 for placebo (p<0.001) — an 83% reduction from baseline. Severity scores dropped 1.4 points vs 0.3 (p<0.001), and sleep improved. No serious adverse events or discontinuations were reported. This follows the top-line data release this morning and the 8-K filed today; the detailed numbers and clean safety profile strengthen the case for a best-in-class non-hormonal option. Shares jumped 33% on the data. Phase 3 validation is the next major catalyst.
At the time of this announcement, ABCL was trading at $9.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9B. The 52-week trading range was $2.75 to $10.01. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Benzinga.